milvexian: Clinical Trials

26 trials of milvexian, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 2 active not recruiting. 21 Phase 1, 3 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 121Completed 21
Phase 23Completed 3
Phase 33Active not recruiting 2, Completed 1

Follow milvexian: new trials by email Literature Review of milvexian trials Research Report on milvexian

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Milvexian, Apixaban, Placebo - Atrial Fibrillation
Phase 3Active not recruitingJanssen Research & Development, LLC202842023-04-112026-11-03
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Milvexian, Placebo - Acute Coronary Syndrome
Phase 3CompletedJanssen Research & Development, LLC141942023-04-072026-07-06
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Milvexian, Placebo - Ischemic Stroke; Ischemic Attack, Transient
Phase 3Active not recruitingJanssen Research & Development, LLC125232023-02-152026-09-25
A Study of Milvexian in Healthy Adult Females
Milvexian, Midazolam, Ethinylestradiol - Healthy Female
Phase 1CompletedJanssen Pharmaceutica N.V., Belgium202023-01-252025-03-30
A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants
BMS-986177 Oral Solution, [14C]BMS-986177 Solution for Infusion, BMS-986177 Spray-dried Dispersion Capsules - Healthy Volunteers
Phase 1CompletedBristol-Myers Squibb172021-07-162023-08-21
A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
Milvexian, Atorvastatin - Healthy
Phase 1CompletedJanssen Pharmaceutica N.V., Belgium232021-06-072025-03-30
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
Milvexian - Healthy
Phase 1CompletedJanssen Research & Development, LLC1152021-04-142025-05-23
A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants
JNJ-70033093 - Healthy
Phase 1CompletedJanssen Research & Development, LLC402021-03-082025-03-30
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
Milvexian, 4-Factor Prothrombin Complex Concentrate (4F-PCC), Recombinant Human Factor VIIa (rFVIIa) - Healthy
Phase 1CompletedJanssen Research & Development, LLC522020-07-272025-08-15
A Study of JNJ-70033093 in Healthy Participants
JNJ-70033093 - Healthy
Phase 1CompletedJanssen Research & Development, LLC242020-06-262025-03-30
A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
JNJ-70033093, Placebo - Healthy
Phase 1CompletedJanssen Research & Development, LLC662020-01-102025-04-27
A Study of JNJ-70033093 and Digoxin in Healthy Participants
JNJ-70033093, Digoxin - Healthy
Phase 1CompletedJanssen Research & Development, LLC302020-01-092025-03-30
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg - Arthroplasty, Replacement, Knee
Phase 2CompletedJanssen Research & Development, LLC12422019-06-172025-03-30
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
BMS-986177 - Thrombosis
Phase 1CompletedBristol-Myers Squibb92019-05-022019-10-04
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
BMS-986177, Placebo, Clopidogrel - Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
Phase 2CompletedBristol-Myers Squibb23662019-01-272023-06-12
A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
BMS-986177, Placebo (for BMS-986177), Clopidogrel - Healthy Volunteers
Phase 1CompletedBristol-Myers Squibb1132018-10-042021-09-29
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
BMS-986177 - Thrombosis
Phase 1CompletedBristol-Myers Squibb262018-03-012018-11-14
Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants
BMS-986177 - Thrombosis
Phase 1CompletedBristol-Myers Squibb122017-11-152018-03-14
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
Aspirin, BMS-986177, Placebo - Healthy Volunteers
Phase 1CompletedBristol-Myers Squibb202017-10-182018-01-19
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
BMS-986177 - Thrombosis
Phase 1CompletedBristol-Myers Squibb242017-07-132022-06-10

Showing 20 of 26. Sign in to see all of them.

Conditions studied

Thrombosis (9)  ·  Ischemic Stroke (2)  ·  Acute Coronary Syndrome (1)  ·  Atrial Fibrillation (1)  ·  Ischemic Attack, Transient (1)  ·  Renal Insufficiency (1)  ·  Renal Insufficiency, Chronic (1)  ·  Stroke (1)

Sponsors

Bristol-Myers Squibb (14)  ·  Janssen Research & Development, LLC (10)  ·  Janssen Pharmaceutica N.V., Belgium (2)

Countries

United States (15)  ·  Belgium (10)  ·  United Kingdom (6)  ·  Argentina (5)  ·  Brazil (5)  ·  Canada (5)  ·  China (5)  ·  Greece (5)  ·  Hungary (5)  ·  Israel (5)  ·  Italy (5)  ·  Japan (5)  ·  Poland (5)  ·  Spain (5)  ·  Australia (4)

Results publications

PMID 38038437, PMID 34780683, PMID 35262846, PMID 35641780, PMID 35906349, PMID 36564395, PMID 38101902, PMID 39025971, PMID 39214801, PMID 39986336, PMID 41791675, PMID 42440100, PMID 42670965

NIH funding

2019 (2), 2015 (1), 2018 (1)